Liposomal encapsulation is a drug delivery strategy with many advantages, such as improved bioavailability, ability to carry large drug loads, as well as controllability and specificity towards various targeted diseased tissues. Currently, most preparation techniques require an additional extrusion or filtering step to obtain monodisperse liposomes with the size of less than 100 nm. In this study, a compact liposome extruder was designed at a cost of $4.00 and used to synthesize liposome suspensions with defined particle size and high homogeneity for Murrayafoline A (Mu-A) loading and release. The synthesized MuA-loaded liposomes displayed a biphasic drug release and remained stable under the storage condition of 4°C. They also significantly reduced the viability of HepG2 cells in the cancer spheroids by 25%. The low-cost, flexible liposome extruder would allow the researchers to study liposomes and their applications in a cost-effective manner.
KoogLGandekTBNagelkerkeA. Liposomes and extracellular vesicles as drug delivery systems: a comparison of composition, pharmacokinetics, and functionalization. Adv Healthc Mater2022; 11: 2100639.
2.
TangLLiJZhaoQ, et al.Advanced and innovative nano-systems for anticancer targeted drug delivery. Pharmaceutics2021; 13: 1151.
3.
AkbarzadehARezaei-SadabadyRDavaranS, et al.Liposome: classification, preparation, and applications. Nanoscale Res Lett2013; 8: 102.
4.
FramptonJE. Liposomal irinotecan: a review in metastatic pancreatic adenocarcinoma. Drugs2020; 80: 1007–1018.
5.
GeorgeTAChenMMCzosseckA, et al.Liposome-encapsulated anthraquinone improves efficacy and safety in triple negative breast cancer. J Control Release2022; 342: 31–43.
6.
SchillerGJDamonLECoutreSE, et al.High-dose vincristine sulfate liposome injection, for advanced, relapsed, or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia in an adolescent and young adult subgroup of a phase 2 clinical trial. J Adolesc Young Adult Oncol2018; 7: 546–552.
7.
ZhangLKongLHeS, et al.The anti-ovarian cancer effect of RPV modified paclitaxel plus schisandra B liposomes in SK-OV-3 cells and tumor-bearing mice. Life Sci2021; 285: 120013.
8.
TatipamulaVBKukavicaB. Phenolic compounds as antidiabetic, anti-inflammatory, and anticancer agents and improvement of their bioavailability by liposomes. Cell Biochem Funct2021; 39: 926–944.
9.
LiuJChiDPanS, et al.Effective co-encapsulation of doxorubicin and irinotecan for synergistic therapy using liposomes prepared with triethylammonium sucrose octasulfate as drug trapping agent. Int J Pharm2019; 557: 264–272.
10.
WangXLiuYXuW, et al.Irinotecan and berberine co-delivery liposomes showed improved efficacy and reduced intestinal toxicity compared with Onivyde for pancreatic cancer. Drug Deliv Transl Res2021; 11: 2186–2197.
11.
GhoshSLalaniRMaitiK, et al.Synergistic co-loading of vincristine improved chemotherapeutic potential of pegylated liposomal doxorubicin against triple negative breast cancer and non-small cell lung cancer. Nanomedicine: Nanotechnology, Biol Med2021; 31: 102320.
12.
WangYYuJLiD, et al.Paclitaxel derivative-based liposomal nanoplatform for potentiated chemo-immunotherapy. J Control Release2022; 341: 812–827.
13.
WangTHeWDuY, et al.Redox-sensitive irinotecan liposomes with active ultra-high loading and enhanced intracellular drug release. Colloids Surf B: Biointerfaces2021; 206: 111967.
14.
KaddahSKhreichNKaddahF, et al.Corticoids modulate liposome membrane fluidity and permeability depending on membrane composition and experimental protocol design. Biochimie2018; 153: 33–45.
15.
ImmordinoMLDosioFCattelL. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine2006; 1: 297–315.
16.
NobleWHangerDPMillerCCJ, et al.The importance of Tau phosphorylation for neurodegenerative diseases. Front Neurol2013; 4: 83. DOI: 10.3389/fneur.2013.00083.
17.
SarafSJainATiwariA, et al.Advances in liposomal drug delivery to cancer: An overview. J Drug Deliv Sci Technol2020; 56: 101549.
18.
MayerLDHopeMJCullisPR. Vesicles of variable sizes produced by a rapid extrusion procedure. Biochim Biophys Acta (Bba) - Biomembranes1986; 858: 161–168.
19.
ZhangH. Thin-film hydration followed by extrusion method for liposome preparation. In: D’SouzaGGM (ed) Liposomes. New York, NY: Springer New York, pp. 17–22.
20.
HarashimaHSakataKFunatoK, et al.Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes. Pharm Res1994; 11: 402–406.
21.
FrézardF.Liposomes: from biophysics to the design of peptide vaccines. Braz J Med Biol Res1999; 32: 181–189.
22.
HunterDGFriskenBJ. Effect of extrusion pressure and lipid properties on the size and polydispersity of lipid vesicles. Biophysical J1998; 74: 2996–3002.
23.
BergerNSachseABenderJ, et al.Filter extrusion of liposomes using different devices: comparison of liposome size, encapsulation efficiency, and process characteristics. Int J Pharm2001; 223: 55–68.
24.
SzokaFPapahadjopoulosD. Comparative properties and methods of preparation of lipid vesicles (liposomes). Annu Rev Biophys Bioeng1980; 9: 467–508.
25.
MacDonaldRCMacDonaldRIMencoBPhM, et al.Small-volume extrusion apparatus for preparation of large, unilamellar vesicles. Biochim Biophys Acta (Bba) - Biomembranes1991; 1061: 297–303.
26.
DeshpandeSDekkerC. On-chip microfluidic production of cell-sized liposomes. Nat Protoc2018; 13(5): 856–874.
27.
HanJ-HKimYJungS-H, et al.Murrayafoline A induces a G0/G1 -phase arrest in platelet-derived growth factor-stimulated vascular smooth muscle cells. Korean J Physiol Pharmacol2015; 19: 421.
28.
KimJHYoonJ-YKwonSJ, et al.Inhibitory components from glycosmis stenocarpa on pepper mild mottle virus. J Microbiol Biotechnol2016; 26: 2138–2140.
29.
TranT. Research on Isolation, Synthesis, Metabolism and Biological Effects Evaluation of Murrayafoline A from Glycosmis Stenocarpa (Drake) of Vietnam. PhD Dissertation. Vietnam: Graduate University of Sciences and Technology-Vietnam Academy of Science and Technology, 2017.
30.
KowalskaAKalinowska-LisU. 18 β -Glycyrrhetinic acid: its core biological properties and dermatological applications. Int J Cosmet Sci2019; 41: 325–331.
31.
SunYDaiCZhengY, et al.Binding effect of fluorescence labeled glycyrrhetinic acid with GA receptors in hepatocellular carcinoma cells. Life Sci2017; 188: 186–191.
32.
ChenJChenYChengY, et al.Modifying glycyrrhetinic acid liposomes with liver-targeting ligand of galactosylated derivative: preparation and evaluations. Oncotarget2017; 8: 102046–102066.
33.
Thuy TTTCuongNMToanTQ, et al.Synthesis of novel derivatives of murrayafoline A and their inhibitory effect on LPS-stimulated production of pro-inflammatory cytokines in bone marrow-derived dendritic cells. Arch Pharm Res2013; 36: 832–839.
34.
XiangBCaoD-Y. Preparation of drug liposomes by thin-film hydration and homogenization. In: LuW-LQiX-R (eds). Liposome-Based Drug Delivery Systems. Berlin, Heidelberg: Springer Berlin Heidelberg, pp. 1–11.
35.
FanYAvciNGNguyenDT, et al.Engineering a high-throughput 3-D In Vitro glioblastoma model. IEEE J Transl Eng Health Med2015; 3: 1–8.
36.
LiuD-ZHsiehY-LChangS-Y, et al.Microcalorimetric studies on the physical stability of poly-ethylene glycol-grafted liposome. Colloids Surf A: Physicochem Eng Asp2003; 212: 227–234.
37.
Hernández-CasellesTVillalaínJGómez-FernándezJC. Stability of liposomes on long term storage. J Pharm Pharmacol2011; 42: 397–400.
38.
ZhouXTaoHShiK-H. Development of a nanoliposomal formulation of erlotinib for lung cancer and in vitro/in vivo antitumoral evaluation. Drug Des Devel Ther2018; 12: 1–8.
39.
PreparationSingh.characterization, and in vitro release study of albendazole-encapsulated nanosize liposomes. IJN2010: 101.
40.
LeNTTVuMTNguyenNH, et al.Preparation and in vitro evaluation of PEGylated liposomes as effective nanocarrier for delivery of oxaliplatin. J Mater Res2021; 36: 475–486.
41.
SukJSXuQKimN, et al.PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev2016; 99: 28–51.
42.
TangZ-HLiTChangL-L, et al.Glycyrrhetinic acid triggers a protective autophagy by activation of extracellular regulated protein kinases in hepatocellular carcinoma cells. J Agric Food Chem2014; 62: 11910–11916.
43.
SatomiYNishinoHShibataS. Glycyrrhetinic acid and related compounds induce G1 arrest and apoptosis in human hepatocellular carcinoma HepG2. Anticancer Res2005; 25: 4043–4047.
44.
ParkJW. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res2002; 43: 1–5.
45.
GumprichtEDahlRDevereauxMW, et al.Licorice compounds glycyrrhizin and 18β-glycyrrhetinic acid are potent modulators of bile acid-induced cytotoxicity in rat hepatocytes. J Biol Chem2005; 28011: 10556–10563.
46.
JeongHGYouHJParkSJ, et al.Hepatoprotective effects of 18β-glycyrrhetinic acid on carbon tetrachloride-induced liver injury: inhibition of cytochrome P450 2E1 expression. Pharmacol Res2002; 463: 221–227.
47.
ChoiHGwakJChoM, et al.Murrayafoline A attenuates the Wnt/β-catenin pathway by promoting the degradation of intracellular β-catenin proteins. Biochem Biophysical Research Communications2010; 391(1): 915–920.
